AAAAAA
Results:
1-21
|
Results: 21
Authors:
Lespagnard, L
Gancberg, D
Maaroufi, Y
Leclercq, G
Larsimont, D
Verhest, A
Citation: L. Lespagnard et al., In situ amplification of oestrogen receptor alpha mRNA in breast cancer cell lines and tumours, J CL PATH-M, 54(3), 2001, pp. 197-199
Authors:
Di Leo, A
Larsimont, D
Gancberg, D
Jarvinen, T
Beauduin, M
Vindevoghel, A
Michel, J
Focan, C
Ries, F
Gobert, P
Closon-Dejardin, MT
Dolci, S
Rouas, G
Paesmans, M
Lobelle, JP
Isola, J
Piccart, MJ
Citation: A. Di Leo et al., HER-2 and topo-isomerase II alpha as predictive markers in a population ofnode-positive breast cancer patients randomly treated with adjuvant CMF orepirubicin plus cyclophosphamide, ANN ONCOL, 12(8), 2001, pp. 1081-1089
Authors:
Cardoso, F
Di Leo, A
Larsimont, D
Gancberg, D
Rouas, G
Dolci, S
Ferreira, F
Paesmans, M
Piccart, M
Citation: F. Cardoso et al., Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes, ANN ONCOL, 12(5), 2001, pp. 615-620
Authors:
Sotiriou, C
Lacroix, M
Lespagnard, L
Larsimont, D
Paesmans, M
Body, JJ
Citation: C. Sotiriou et al., Interleukins-6 and-11 expression in primary breast cancer and subsequent development of bone metastases, CANCER LETT, 169(1), 2001, pp. 87-95
Authors:
Gancberg, D
Scourneau, M
Verdebout, JM
Larsimont, D
Verhest, A
Citation: D. Gancberg et al., Detection of extra chromosomes 12 by fluorescent in situ hybridization (FISH) in ovarian stromal tumors. Study of 12 cases and review of the literature, ANN PATHOL, 21(5), 2001, pp. 393-398
Authors:
Diedhiou, A
Larsimont, D
Vandeweyer, E
Andry, G
Somerhausen, NDA
Citation: A. Diedhiou et al., Fibrosarcomatous variant of dermatofibrosarcoma protuberans: clinicopathologic analysis of 4 cases, ANN PATHOL, 21(2), 2001, pp. 164-167
Authors:
Lacroix, M
Querton, G
Hennebert, P
Larsimont, D
Leclercq, G
Citation: M. Lacroix et al., Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immmocytochemical assay, and northern blot: a comparison, BREAST CANC, 67(3), 2001, pp. 263-271
Authors:
Piccart, M
Lohrisch, C
Di Leo, A
Larsimont, D
Citation: M. Piccart et al., The predictive value of HER2 in breast cancer, ONCOL-BASEL, 61, 2001, pp. 73-82
Authors:
Dequanter, D
Hertens, D
Veys, I
Nogaret, JM
Larsimont, D
Bourgeois, P
Citation: D. Dequanter et al., Sentinel lymph node involvement in T0T1 breast tumors., ANN CHIR, 126(7), 2001, pp. 654-658
Authors:
Maaroufi, Y
Lacroix, M
Lespagnard, L
Journe, F
Larsimont, D
Leclercq, G
Citation: Y. Maaroufi et al., Estrogen receptor of primary breast cancers: evidence for intracellular proteolysis, BREAST CA R, 2(6), 2000, pp. 444-454
Authors:
Gancberg, D
Lespagnard, L
Rouas, G
Paesmans, M
Piccart, M
Di Leo, A
Nogaret, JM
Hertens, D
Verhest, A
Larsimont, D
Citation: D. Gancberg et al., Sensitivity of HER-2/neu antibodies in archival tissue samples of invasivebreast carcinomas - Correlation with oncogene amplification in 160 cases, AM J CLIN P, 113(5), 2000, pp. 675-682
Authors:
Theunis, A
Andre, J
Larsimont, D
Song, M
Citation: A. Theunis et al., Epithelioid sarcoma: A puzzling soft tissue neoplasm in a child, DERMATOLOGY, 200(2), 2000, pp. 179-180
Authors:
Di Leo, A
Crown, J
Nogaret, JM
Duffy, K
Bartholomeus, S
Dolci, S
Rowan, S
O'Higgins, N
Paesmans, M
Larsimont, D
Riva, A
Piccart, MJ
Citation: A. Di Leo et al., A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer, ANN ONCOL, 11(2), 2000, pp. 169-175
Authors:
Gancberg, D
Feoli, F
Hamels, J
de Saint-Aubain, N
Andre, J
Rouas, G
Verhest, A
Larsimont, D
Citation: D. Gancberg et al., Trisomy 6 in Merkel cell carcinoma: a recurrent chromosomal aberration, HISTOPATHOL, 37(5), 2000, pp. 445-451
Authors:
Seo, HS
Larsimont, D
Ma, Y
Laios, I
Leclercq, G
Citation: Hs. Seo et al., Regulation of estrogen receptor levels by ligand-induced release of compound(s) in MCF-7 cells, MOL C ENDOC, 164(1-2), 2000, pp. 19-29
Authors:
Tanner, M
Gancberg, D
Di Leo, A
Larsimont, D
Rouas, G
Piccart, MJ
Isola, J
Citation: M. Tanner et al., Chromogenic in situ hybridization - A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples, AM J PATH, 157(5), 2000, pp. 1467-1472
Authors:
Tueche, SG
Nguyen, H
Larsimont, D
Andry, G
Citation: Sg. Tueche et al., Late onset of tonsillar metastasis from breast cancer, EUR J SUR O, 25(4), 1999, pp. 439-440
Authors:
Lespagnard, L
Gancberg, D
Rouas, G
Leclercq, G
Somerhausen, ND
Di Leo, A
Piccart, M
Verhest, A
Larsimont, D
Citation: L. Lespagnard et al., Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: A study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome, INT J CANC, 84(3), 1999, pp. 309-314
Authors:
Ghnassia, JP
Vilain, MO
Coindre, JM
Bertrand, G
Chateau, MC
Collin, F
Depardieu, C
Fiche, M
Guillou, L
Jacquemier, J
Larsimont, D
Le Doussal, V
Leroux-Broussier, A
Mandard, AM
Marques, B
Ranchere, D
Sastre, X
Terrier, P
Trassard, M
Citation: Jp. Ghnassia et al., Management of adult soft tissue sarcomas: recommendations for pathologistsby the FNCLCC Sarcoma Group., ANN PATHOL, 18(6), 1998, pp. 505-511
Authors:
Elnakadi, I
Mehdi, A
Franck, S
Roger, T
Larsimont, D
Pector, JC
Citation: I. Elnakadi et al., Cecal infarct - Report of a case, DIS COL REC, 41(12), 1998, pp. 1585-1586
Authors:
Heymans, O
Lemaitre, J
Choghari, C
Larsimont, D
Ohana, M
Drijski, J
Nogaret, JM
Citation: O. Heymans et al., Leiomyosarcoma of the mesocolon, ACT CHIR B, 98(6), 1998, pp. 261-263
Risultati:
1-21
|